Ellen Rohde

2.4k total citations · 2 hit papers
21 papers, 550 citations indexed

About

Ellen Rohde is a scholar working on Molecular Biology, Biomedical Engineering and Oncology. According to data from OpenAlex, Ellen Rohde has authored 21 papers receiving a total of 550 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Biomedical Engineering and 4 papers in Oncology. Recurrent topics in Ellen Rohde's work include Drug Transport and Resistance Mechanisms (4 papers), CRISPR and Genetic Engineering (4 papers) and Nanoplatforms for cancer theranostics (3 papers). Ellen Rohde is often cited by papers focused on Drug Transport and Resistance Mechanisms (4 papers), CRISPR and Genetic Engineering (4 papers) and Nanoplatforms for cancer theranostics (3 papers). Ellen Rohde collaborates with scholars based in United States, Germany and Canada. Ellen Rohde's co-authors include Andrew M. Bellinger, Sekar Kathiresan, Amit V. Khera, Anne Marie Mazzola, Maurine Braun, Colin Platt, Scott B. Vafai, Richard Lee, Stephen Naylor and Douglas H. Johnson and has published in prestigious journals such as Circulation, Nature Communications and Journal of the American College of Cardiology.

In The Last Decade

Ellen Rohde

21 papers receiving 531 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models

2022 132 citations Richard Lee, Anne Marie Mazzola et al. Circulation profile →
GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy

2023 93 citations Lisa N. Kasiewicz, Souvik Biswas et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ellen Rohde United States	12	257	89	72	66	49	21	550
Geng Xu China	14	183 0.7×	51 0.6×	36 0.5×	147 2.2×	53 1.1×	50	585
Paola Spitalieri Italy	14	288 1.1×	79 0.9×	43 0.6×	31 0.5×	22 0.4×	29	478
Luying Yang China	14	197 0.8×	93 1.0×	48 0.7×	144 2.2×	24 0.5×	37	588
Yingying Gong China	15	309 1.2×	56 0.6×	64 0.9×	52 0.8×	13 0.3×	32	522
Tomokazu Yoshida Japan	17	346 1.3×	47 0.5×	82 1.1×	143 2.2×	52 1.1×	37	893
Hyo Min Park United States	9	258 1.0×	106 1.2×	59 0.8×	76 1.2×	22 0.4×	11	519
Juyong Wang China	13	203 0.8×	78 0.9×	111 1.5×	52 0.8×	24 0.5×	32	553
Yuancheng Li China	13	200 0.8×	57 0.6×	44 0.6×	56 0.8×	78 1.6×	44	532
Rui Ling China	17	344 1.3×	58 0.7×	76 1.1×	118 1.8×	13 0.3×	60	654

Countries citing papers authored by Ellen Rohde

Since Specialization

Citations

This map shows the geographic impact of Ellen Rohde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Rohde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Rohde more than expected).

Fields of papers citing papers by Ellen Rohde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Rohde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Rohde. The network helps show where Ellen Rohde may publish in the future.

Co-authorship network of co-authors of Ellen Rohde

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Rohde. A scholar is included among the top collaborators of Ellen Rohde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Rohde. Ellen Rohde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rohde, Ellen, Richard Lee, Anne Marie Mazzola, et al.. (2025). † VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies. Journal of clinical lipidology. 19(3). e68–e68. 1 indexed citations

Macias, Luis A., et al.. (2025). Ion Mobility Gas-Phase Separation Enhances Top-Down Mass Spectrometry of Heavily Modified Guide RNA. Analytical Chemistry. 97(17). 9430–9437. 2 indexed citations

Lee, Richard, Anne Marie Mazzola, Taiji Mizoguchi, et al.. (2024). An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves precise and durable liver editing in nonclinical studies. Atherosclerosis. 395. 118496–118496. 4 indexed citations

Kasiewicz, Lisa N., Souvik Biswas, Chaitali Dutta, et al.. (2023). GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. Nature Communications. 14(1). 2776–2776. 93 indexed citations breakdown →

Macias, Luis A., Sara P. Garcia, Yue Wu, et al.. (2023). Spacer Fidelity Assessments of Guide RNA by Top-Down Mass Spectrometry. ACS Central Science. 9(7). 1437–1452. 8 indexed citations

Lee, Richard, Chaitali Dutta, Hui‐Ting Hsu, et al.. (2023). PRECLINICAL DATA SUPPORTING POTENTIAL EFFICACY OF VERVE-201 - AN INVESTIGATIONAL CRISPR BASE EDITING MEDICINE TARGETING ANGPTL3 - IN PRIMARY HUMAN CELLS, MICE, AND NON-HUMAN PRIMATES. Journal of the American College of Cardiology. 81(8). 1115–1115. 9 indexed citations

Lee, Richard, Anne Marie Mazzola, Maurine Braun, et al.. (2022). Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models. Circulation. 147(3). 242–253. 132 indexed citations breakdown →

Metcalf, Chester A., Sönke Svenson, Jungyeon Hwang, et al.. (2019). Discovery of a Novel Cabazitaxel Nanoparticle–Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects Using a β-Cyclodextrin–PEG Copolymer Based Delivery Platform. Journal of Medicinal Chemistry. 62(21). 9541–9559. 7 indexed citations

Weinreb, Paul H., R. Blake Pepinsky, Danielle Graham, et al.. (2018). Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration. Fluids and Barriers of the CNS. 15(1). 10–10. 50 indexed citations

10.

Pham, Elizabeth, Melissa Yin, Christian Peters, et al.. (2016). Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer. Cancer Research. 76(15). 4493–4503. 55 indexed citations

11.

Scannevin, Robert H., Sowmya Chollate, Melanie S. Brennan, et al.. (2015). BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease. Neuropharmacology. 103. 57–68. 11 indexed citations

12.

Peters, Christian, Douglas Lazarus, Donna M. Brown, et al.. (2015). Abstract B37: Selective tumor localization of CRLX101, a novel nanoparticle-drug conjugate. Molecular Cancer Therapeutics. 14(12_Supplement_2). B37–B37. 2 indexed citations

13.

Li, Ming, Jing Jing, Hui Xu, et al.. (2012). Mars: Bringing The Automation of Small-Molecule Bioanalytical Sample Preparations to A New Frontier. Bioanalysis. 4(11). 1311–1326. 12 indexed citations

14.

Xiao, Guangqing, et al.. (2012). Cerebrospinal Fluid Can Be Used as a Surrogate to Assess Brain Exposures of Breast Cancer Resistance Protein and P-Glycoprotein Substrates. Drug Metabolism and Disposition. 40(4). 779–787. 25 indexed citations

15.

Xin, Zhili, Hairuo Peng, Andrew Zhang, et al.. (2011). Discovery of 4-aminomethylphenylacetic acids as γ-secretase modulators via a scaffold design approach. Bioorganic & Medicinal Chemistry Letters. 21(24). 7277–7280. 15 indexed citations

16.

Peng, Hairuo, Tina Talreja, Zhili Xin, et al.. (2011). Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator. ACS Medicinal Chemistry Letters. 2(10). 786–791. 17 indexed citations

17.

Ma, Bin, Kevin M. Guckian, Edward Yin-Shiang Lin, et al.. (2010). Stereochemistry–activity relationship of orally active tetralin S1P agonist prodrugs. Bioorganic & Medicinal Chemistry Letters. 20(7). 2264–2269. 9 indexed citations

18.

Mehl, John T., et al.. (2003). Automated protein identification using atmospheric‐pressure matrix‐assisted laser desorption/ionization. Rapid Communications in Mass Spectrometry. 17(14). 1600–1610. 7 indexed citations

19.

Rohde, Ellen, Andy J. Tomlinson, Douglas H. Johnson, & Stephen Naylor. (1998). Protein analysis by membrane preconcentration–capillary electrophoresis: systematic evaluation of parameters affecting preconcentration and separation. Journal of Chromatography B Biomedical Sciences and Applications. 713(2). 301–311. 38 indexed citations

20.

Rohde, Ellen, Carla Vogt, & William R. Heineman. (1998). The analysis of fountain pen inks by capillary electrophoresis with ultraviolet/visible absorbance and laser‐induced fluorescence detection. Electrophoresis. 19(1). 31–41. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact